English
Home > Products > CAS:35380-71-3

China CAS:35380-71-3 Manufacturer

We hold strengthening and perfecting our items and repair. At the same time, we get the job done actively to do research and progress for CAS:35380-71-3, We welcome new and aged buyers from all walks of lifetime to make contact with us for potential small business associations and mutual success!
CAS:35380-71-3, Our company warmly invites domestic and overseas customers to come and negotiate business with us. Let us join hands to create a brilliant tomorrow! We're looking forward to cooperating with you sincerely to achieve a win-win situation. We promise to try our best to supply you with high quality and efficient services.

Related Products

Hot Products

  • Progesterone

    Progesterone

    Progesterone has EP, USP, CP, JP, IP and KP specifications. CEP available, EU-GMP,FDA approved.

    CAS:57-83-0

  • Ganciclovir

    Ganciclovir

    Ganciclovir has CP ,EP, USP specification. DMF and GMP approved.

    CAS:82410-32-0

  • Valganciclovir Hydrochloride

    Valganciclovir Hydrochloride

    Valganciclovir Hydrochloride has USP specification. DMF approved.

    CAS:175865-59-5

  • Mirabegron

    Mirabegron

    Mirabegron has In-house specification. DMF approved..

    CAS:223673-61-8

  • 17a-Hydroxyprogesterone Acetate

    17a-Hydroxyprogesterone Acetate

    17a-Hydroxyprogesterone Acetate is an endogenous progesteroid hormone similar to progesterone.

    CAS:302-23-8

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Related Blog
  • Reviews

  • 2019 CPhI China Exhibition Shanghai

    June 2019
    CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

  • 2021 API Exhibition Guangzhou

    May 2021
    API China is a well-established comprehensive pharmaceuticals and chemicals show in Chinese pharmaceutical industry. With more than 40 years’ experience in China, it has been a well-known celebration for all parties involved in Chinese Pharmaceutical market.

  • 2024 VIETNAM MEDI-PHARM EXPO

    VIETNAM MEDI-PHARM EXPO 2024 will be held at Saigon Exhibition & Convention Center – SECC from August 1 to 3, our booth number is I19.

  • CPHI China 2025 | Looking forward to meeting you!

    CPHI China will be staged at Shanghai New International Expo Center on June 24-26, 2025 together with ICSE & PMEC China,our booth number is W1G20(b).

  • Visit us at CPHI Frankfurt - Booth 12.1C3!

    CPHI Frankfurt 2025 will be held at Messe Frankfurt from October 28 to 30, our booth number is 12.1C3.

  • How Can Intermediates Category Solutions Streamline Your Production Process

    As someone who has spent over two decades navigating the complexities of industrial production, I've seen firsthand how bottlenecks in the middle stages can derail entire operations. That’s why I was particularly impressed when I began working with solutions from the Intermediates Category. For any production manager, finding tools that seamlessly integrate and accelerate the core of your workflow is the ultimate goal. This is where the strategic approach from Humanwell truly shines, offering a refined path to efficiency that many of us have been searching for.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept